Apnimed
Apnimed is a clinical-stage company advancing oral medicines to treat Obstructive Sleep Apnea and related disorders.
Apnimed is a clinical-stage company advancing oral medicines to treat Obstructive Sleep Apnea and related disorders.
Apnimed is a clinical-stage company founded in 2017, with a focus on advancing oral medicines to address Obstructive Sleep Apnea (OSA) and related disorders. The company's slogan sums up its mission succinctly: "Apnimed is a clinical-stage company advancing oral medicines to treat Obstructive Sleep Apnea and related disorders." This reflects the company's commitment to developing innovative solutions for a pressing healthcare issue. Based in the United States, Apnimed recently secured a substantial $79.75M Series C investment on 23 December 2022. The investment came from a consortium of well-regarded investors including Tao Capital Partners, Alpha Wave Global, Sectoral Asset Management, and Alpha Wave Ventures. This funding will likely enable Apnimed to advance its clinical-stage programs and drive further innovation in the treatment of OSA and related disorders.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $79.75M | 4 |
|
23 Dec 2022 |
| Series C | $62.50M | 5 |
|
04 May 2022 |
| Series B | $25.00M | 1 | Morningside Venture Investments | 25 Mar 2021 |
| Venture Round | $15.00M | - | 31 Mar 2020 | |
| Venture Round | $25.58M | - | 25 Jun 2018 |
No recent news or press coverage available for Apnimed.
We care about your data, and we'd love to use cookies make your experience better.
